Sage Therapeutics Inc. (NASDAQ:SAGE) – Equities research analysts at Leerink Swann issued their Q3 2016 EPS estimates for shares of Sage Therapeutics in a report released on Tuesday. Leerink Swann analyst P. Matteis expects that the brokerage will post earnings per share of ($1.16) for the quarter. Leerink Swann currently has a “Outperform” rating and a $68.00 price target on the stock. Leerink Swann also issued estimates for Sage Therapeutics’ Q4 2016 earnings at ($1.12) EPS, FY2016 earnings at ($4.34) EPS, FY2017 earnings at ($5.50) EPS, FY2018 earnings at ($5.48) EPS and FY2019 earnings at ($3.14) EPS.
SAGE has been the subject of a number of other research reports. Raymond James Financial Inc. initiated coverage on Sage Therapeutics in a research note on Tuesday, September 13th. They set an “outperform” rating and a $75.00 price objective for the company. Canaccord Genuity set a $110.00 price objective on Sage Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 6th. Cowen and Company reiterated a “buy” rating on shares of Sage Therapeutics in a research note on Monday, September 19th. Chardan Capital reiterated a “sell” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Finally, Zacks Investment Research lowered Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. Sage Therapeutics currently has a consensus rating of “Buy” and an average target price of $67.83.
Shares of Sage Therapeutics (NASDAQ:SAGE) opened at 43.50 on Thursday. The firm’s 50-day moving average price is $42.01 and its 200-day moving average price is $37.01. Sage Therapeutics has a 12 month low of $26.28 and a 12 month high of $62.64. The stock’s market capitalization is $1.40 billion.
Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by $0.06.
A number of large investors have recently bought and sold shares of SAGE. Legal & General Group Plc boosted its stake in Sage Therapeutics by 17.2% in the first quarter. Legal & General Group Plc now owns 4,146 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 607 shares during the last quarter. Teacher Retirement System of Texas raised its position in Sage Therapeutics by 38.2% in the second quarter. Teacher Retirement System of Texas now owns 3,522 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 973 shares during the period. Bessemer Group Inc. raised its position in Sage Therapeutics by 3.1% in the first quarter. Bessemer Group Inc. now owns 33,849 shares of the biopharmaceutical company’s stock worth $1,085,000 after buying an additional 1,019 shares during the period. BNP Paribas Arbitrage SA raised its position in Sage Therapeutics by 129.1% in the third quarter. BNP Paribas Arbitrage SA now owns 2,369 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,335 shares during the period. Finally, ProShare Advisors LLC raised its position in Sage Therapeutics by 5.9% in the second quarter. ProShare Advisors LLC now owns 27,110 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 1,500 shares during the period. Institutional investors own 82.63% of the company’s stock.
In related news, CFO Kimi Iguchi sold 5,000 shares of Sage Therapeutics stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $49.55, for a total value of $247,750.00. Following the sale, the chief financial officer now directly owns 83,739 shares in the company, valued at approximately $4,149,267.45. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Albert Robichaud sold 22,000 shares of Sage Therapeutics stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $40.00, for a total value of $880,000.00. Following the completion of the sale, the insider now owns 140,222 shares in the company, valued at $5,608,880. The disclosure for this sale can be found here. 5.60% of the stock is owned by corporate insiders.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.